Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Oct 21, 2025 (12 months ago)

Tylenol (Acetaminophen)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Defective Container

Cause type: Packaging defect

Failed child-resistant closures, leaks, cracked containers, or a defective delivery device. Packaging failures risk accidental exposure (especially to children) or product contamination. All packaging defect recalls.

What was recalled

TYLENOL, Acetaminophen, Extra Strength, 24 Caplets, 500mg each, distributed by: Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division, Fort Washington, PA 19034, NDC: 50580-378-04.

Affected NDC 50580-0378-04

Compare with the code on your package — it is the most precise check available.

Drug: Acetaminophen Category: Pain Relief & OTC Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Tylenol Extra Strength
Acetaminophen
NDC 50580-0378
500 mg/1 Tablet, Film Coated
Oral
Kenvue Brands LLC OTC
Recalling firm
Kenvue Brands LLC
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0121-2026 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Acetaminophen recalls

See all
Class II · Moderate risk

Acetaminophen 500mg Caffeine 65mg caplets

Labeling: Label Mix-up. This issue affects the outer box labeling only. The box incorrectly states the ingredients Acetaminophen 500mg and Caffeine 65mg. The inner pouch correctly states the ingredients are Aspirin (NSAID)*500mg and Caffeine 32.5mg.

Ongoing Labeling / mix-up Aero Healthcare NDC 55305-135-01 D-0155-2026
Class II · Moderate risk

Acetaminophen Tablets

cGMP deviations: Due to confirmed consumer complaints received with the observation of tablet discoloration (brown surface on tablets).

Ongoing Failed specification Aurobindo Pharma USA Inc NDC 72288-405-10 D-0471-2025

Other packaging defect recalls from 2025

All packaging defect recalls
Class II · Moderate risk

Ondansetron Orally Disintegrating Tablets

Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling out. Preferred Pharmaceuticals purchased the finished product and repackaged the product for sale.

Ongoing Packaging defect Glenmark Pharmaceuticals Inc., USA NDC 68462-157-13 D-0246-2026
Class II · Moderate risk

Ondansetron ODT Tablets

Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling out. Preferred Pharmaceuticals purchased the finished product and repackaged the product for sale.

Ongoing Packaging defect Preferred Pharmaceuticals, Inc. NDC 68788-8666-01 D-0239-2026